Cancer News and Research

Latest Cancer News and Research

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that data from a phase I single-agent clinical trial of brentuximab vedotin (SGN-35) will be published in the November 4, 2010 issue of the New England Journal of Medicine.

4 Nov 2010

Level of prostate-specific protein after salvage radiation therapy predicts mortality and disease progression

Removal of the prostate gland often eradicates early-stage cancer. But patients whose cancer has spread may need to follow up with what is known as salvage radiation therapy. Researchers at Fox Chase have now determined a better way to monitor outcomes after this procedure.

4 Nov 2010

Frequent long-term use of cell phones may increase cancer risk

Public health concerns have been raised today about the safety of being exposed to radiofrequency (RF) radiation emitted from cell phones. A report released by the Ontario Agency for Health Protection and Promotion (OAHPP) in September 2010 was one of the studies cited as providing evidence that frequent long-term use of cell phones may be associated with an increased risk of cancer.

4 Nov 2010

Advanced Life Sciences awarded $244,479.25 grant under Qualifying Therapeutic Discovery Project

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has been awarded a cash grant under the Qualifying Therapeutic Discovery Project which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.

4 Nov 2010

Picis introduces charge capture solution for oncology treatment centers

Picis today introduced LYNX I/Point, a charge capture solution designed specifically for hospital-owned infusion and oncology treatment centers - where therapies are very expensive and accurately charging for services can be challenging.

4 Nov 2010

New radiotracer application may advance understanding of estrogen-related diseases

A study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory has demonstrated that a molecule "tagged" with a radioactive form of carbon can be used to image aromatase, an enzyme responsible for the production of estrogen, in the human brain. The research, published in the November issue of Synapse, also uncovered that the regions of the brain where aromatase is concentrated may be unique to humans.

4 Nov 2010

HPV vaccine enjoys wide support from medical and public health communities

The vaccine that protects against the potentially cancer-causing human papillomavirus (HPV) enjoys wide support in the medical and public health communities. Yet state laws to require young girls to be vaccinated as a requirement for middle school attendance have aroused controversy with parents, politicians, and even medical and public health experts disagreeing about whether such laws are appropriate.

4 Nov 2010

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced positive preliminary results of a Phase IIa study in inflammatory bowel disease (IBD) with its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release.

4 Nov 2010

Beginner's guide to cancer

An academic from The University of Nottingham has written the first introductory guide to cancer, covering everything from the biology of the disease and why some people are more at risk of developing it than others, to the latest research into prevention, treatment and cure.

4 Nov 2010

Gene fusion prostate cancers susceptible to secondary mutations

Scientists at Weill Cornell Medical College have taken an important step toward a better understanding of prostate cancer by uncovering evidence that it is not one disease, as previously believed, but rather several factors which can be measured and, in the future, destroyed by targeted therapy.

4 Nov 2010

Aestus receives $244,000 grant from QTDP program

Today Aestus Therapeutics, Inc. announced that it has been awarded a $244,000 grant from the U.S. Government's Qualifying Therapeutic Discovery Project program.

4 Nov 2010

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

"For brain cancer patients after surgery, the combined DC-CIK and stem cell therapy from Cellonis Biotechnologies can be a very effective method in preventing cancer recurrence," says renowned cancer doctor Dr. Dinggang Li.

4 Nov 2010

Lentigen awarded $1.23M grant under Patient Protection and Affordable Care Act

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protection and Affordable Care Act.

4 Nov 2010

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.

4 Nov 2010

Jefferson professor named 'Physician of the Year' by CancerCare

Edith P. Mitchell, M.D., clinical professor, Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, and associate director of Diversity Programs for the Kimmel Cancer Center at Jefferson, was recently named 'Physician of the Year' by CancerCare, a national nonprofit organization that provides free, professional support services to anyone affected by cancer: people with cancer, caregivers, children, loved ones, and the bereaved. Dr. Mitchell is being honored for her work in gastrointestinal malignancies.

4 Nov 2010

New findings show combinational therapy effective for patients with DLBCL lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults. If left untreated, it is fatal. The existing treatments have a cure rate that is slightly over 50 percent but destroy healthy cells along with the cancer cells.

4 Nov 2010

Low vitamin D levels linked to cancer progression and death in CLL patients

Researchers at Mayo Clinic have found a significant difference in cancer progression and death in chronic lymphocytic leukemia (CLL) patients who had sufficient vitamin D levels in their blood compared to those who didn't.

4 Nov 2010

Rescu receives $50,000 grant to teach 22 minute CPR course to high school students

Researchers led by St. Michael's Hospital will be teaching a quick, inexpensive method of cardio-pulmonary resuscitation to some Toronto-area high school students this fall.

4 Nov 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has received a grant of $244,479 from the United States Government to help fund the Company's Phase I clinical trial of its lead cancer drug candidate Liposomal Grb-2. The amount of funds awarded was the maximum allocation allowed under the program.

4 Nov 2010

Coronado completes series of private financings

Coronado Biosciences, Inc., a privately held company engaged in innovative oncology drug development, announced completion of a series of private financings in 2010, resulting in aggregate gross proceeds to the Company of approximately $21.6 million.

4 Nov 2010

Cancer News and Research

Latest Cancer News and Research

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

Level of prostate-specific protein after salvage radiation therapy predicts mortality and disease progression

Frequent long-term use of cell phones may increase cancer risk

Advanced Life Sciences awarded $244,479.25 grant under Qualifying Therapeutic Discovery Project

Picis introduces charge capture solution for oncology treatment centers

New radiotracer application may advance understanding of estrogen-related diseases

HPV vaccine enjoys wide support from medical and public health communities

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

Beginner's guide to cancer

Gene fusion prostate cancers susceptible to secondary mutations

Aestus receives $244,000 grant from QTDP program

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

Lentigen awarded $1.23M grant under Patient Protection and Affordable Care Act

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Jefferson professor named 'Physician of the Year' by CancerCare

New findings show combinational therapy effective for patients with DLBCL lymphoma

Low vitamin D levels linked to cancer progression and death in CLL patients

Rescu receives $50,000 grant to teach 22 minute CPR course to high school students

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Coronado completes series of private financings

Industry Focus - Oncology (1st Edition) eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Industry Focus - Oncology (1st Edition) eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in